MMSI Q1 2026 Earnings Call Summary

Summary of Merit Medical Systems (MMSI) Q1 2026 Earnings Call

1. Key Financial Results and Metrics

Total Revenue: $381.9 million, up 7% year-over-year (5% on a constant currency basis).
Organic Growth: 2.7% constant currency growth; 3.7% excluding divested revenue (DualCap product line).
Non-GAAP Operating Margin: Increased to 19.7%, the highest for Q1 in company history.
Non-GAAP EPS: $0.94, a 9% increase year-over-year, exceeding guidance by $0.07.
Free Cash Flow: $25 million, a 26% increase year-over-year.
Balance Sheet: Cash and cash equivalents of $488.1 million; total debt obligations of $747.5 million; net leverage ratio of 1.6x.

2. Strategic Updates and Business Highlights

Acquisition of View Point Medical: Completed on April 1, 2026, for $140 million, enhancing the oncology platform with the OneMark Detection Imaging System, expected to triple the addressable market for breast localization procedures.
New Product Launch: The Resilience Through-the-Scope Esophageal Stent introduced, targeting esophageal fistulas and structures, expected to contribute to endoscopy growth.
Revenue Reporting Changes: Revenue will now be reported in two categories: foundational and therapeutic products, aligning internal and external communications.
Operational Improvements: Enhanced focus on product and commercial priorities across eight platforms, aiming for better alignment and accountability.

3. Forward Guidance and Outlook

2026 Guidance: Updated to reflect acquisition impacts, with total GAAP revenue growth projected at 6.3% to 7.8% year-over-year. Non-GAAP EPS guidance remains at $4.01 to $4.15, reflecting a 5% to 8% increase.
Q2 2026 Expectations: Revenue projected between $400 million and $410 million (5% to 7% growth year-over-year). Non-GAAP EPS expected between $0.90 and $1.00.

4. Bad News, Challenges, or Points of Concern

OEM Business Decline: OEM sales dropped 14% year-over-year, attributed to inventory destocking and macroeconomic pressures, particularly in the APAC region.
Tariff Impact: Anticipated $15 million tariff impact on 2026 non-GAAP EPS, with ongoing uncertainty regarding potential changes in tariff policies.
Geopolitical Risks: Some revenue loss due to shipping issues in the Middle East, although overall impact deemed manageable.

5. Notable Q&A Insights

WRAPSODY Product Progress: Management confirmed satisfaction with WRAPSODY's performance, tracking towards the $7 million revenue target for 2026.
View Point Medical Growth: Expected to ramp from $2 million to $4 million in 2026 to $14 million to $16 million in 2027, with a projected 20% growth rate thereafter.
OEM Business Outlook: Management expressed optimism for mid-single-digit growth in Q2 2026, citing early order trends as encouraging.
Supply Chain Issues: Addressed past supply chain disruptions in the cardiac segment, with ongoing efforts to manage inventory levels and ensure product availability.

Overall, Merit Medical Systems reported a strong start to 2026, marked by solid revenue growth and strategic acquisitions, while navigating challenges in specific business segments and external economic factors.

MMSI — Merit Medical Systems, Inc.